Aplicaciones Geográficas en el Registro Federal de Electores del Instituto Nacional Electoral

Tesis de LicenciaturaLa conformación del padrón electoral se encuentra en constante cambio y actualización, derivado de los ritmos de movilidad de la población y el crecimiento demográfico, sin embargo; con la actualización y depuración permanente de los instrumentos electorales y acompañado de la credencial para votar con fotografía, el Instituto Nacional Electoral, brinda al ciudadano el pleno derecho de poder emitir su sufragio. Parte elemental de lo anterior es la labor desarrollada por una de sus áreas operativas denominada Registro Federal de Electores en la construcción de los instrumentos electorales, y en donde la lista nominal de electores es un insumo indispensable en las casillas electorales instaladas para la elección de nuestros representantes y; que de ello depende, la confiabilidad de los resultados en las elecciones y la credibilidad que se tenga de la población y de los actores políticos. La presente memoria se elabora primordialmente para dar cuenta de mi experiencia profesional por más de 16 años sirviendo como vocal del Registro Federal de Electores al interior del Instituto Nacional Electoral. Considero imprescindible la labor de ésta área, de su estructura operativa, de cada una de las actividades que se desarrollan y que nos permite al interior de cada uno de los trescientos distritos electorales, colaborar en esta actividad registral. Parte primordial de lo anterior es el papel que juega la cartografía electoral, insumo utilizado por cada una de la distintas áreas del Instituto para la planeación de las actividades y que representa la base de todo el enramado Institucional, de ahí la importancia en la labor permanente de los técnicos de actualización cartográfica en su conformación y actualización

An interdisciplinary vision of "Cova Beneito"

Aquest freball ofereix una visió interdisciplimiria i global dels nivells del paleolític mijà i superior de la cova Beneito (Muro del Comtat, Alacant). L'estudi sedimentològic, palinològic i faunístic de la seua dilatada estratigrafia aporta dades imprescindibles per al reconeixement de l'lnterestadial II-III, per a la consolidació de la climatoestratigrafia del Pleistocé Superior i, a més, una comprensió millor de la relació home-medi. El desenvolupamenr cultural ofereix altenatives interessants per a la seqüència mediterrànea i aporta la novetat de I'Aurinyacià evolucionat final a l'ambit valencià. S'hi dedica una apartat a l'estudi d'una tomba ritual secundària solutriogravetiana.The present work attempts to offer an interdisciplinary and global vision on the levels of the Middle and Upper Paleolithic period in "Cova Beneito" (Muro-Alicante-Spain). The sedimentological, palynological and faunistic study of its vast stratigraphy bring forward essential facts for the identification of the midlast glacial stage and for strengthening of the climatostratigraphy of the Upper Pleistocene, as well as for a better reconstruction of the retationship between man and environment. The cultural development supplies interesting alternatives to the Mediterranean sequence, and brings out the novelty of the Evolued Aurignacian in the Valencian area. There is a special section on the study of a secondary Solutrean-Gravettian ritual burial.El presente trabajo ofrece una visión interdisciplinar y global de los niveles del Paleolítico Medio y Superior de Cova Beneito (Muro- Alicante). El estudio sedimentológico, palinológico y faunístico de su dilatada estratigrafía aportan datos imprescindibles para el reconocimiento del Interestadial II-III y el afianzamiento de la climatoestratigrafía del Pleistoceno Superior, así como para una mejor comprensidn de la relación hombre-medio. El desarrollo cultural ofrece alternativas interesantes a tu secuencia mediterránea, aportando la novedad del Auriñaciense evolucionado final al ámbito valenciano. Se dedica un apartado al estudio de un enterramiento ritual secundario Solútreogravetiense

Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry

Objective: The soluble guanylate cyclase stimulator riociguat is approved for the treatment of adult patients with pulmonary arterial hypertension (PAH) and inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) following Phase

III Seminario de Escuela Rural al Día : innovar en el medio rural

Resumen basado en la publicaciónSe recogen las actividades realizadas en un seminario sobre escuela rural celebrado en San Antolín de Ibias (Asturias), los días 30 y 31 de mayo y 1 de junio de 2003. Se estructura en torno a los siguientes apartados: Programa del Seminario, acto de bienvenida, ponencias (Innovar en educación, Desarrollo rural y política de la ruralidad y Comunidades de Aprendizaje), experiencias, comunicaciones, grupos de trabajo y exposiciones realizadas.AsturiasUniversidad de Oviedo.Facultad de Ciencias de la Educación; Calle Aniceto Sela s. n.; 33005 Oviedo; +34985103215; 985103214;ES

Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry

Objective: The soluble guanylate cyclase stimulator riociguat is approved for the treatment of adult patients with pulmonary arterial hypertension (PAH) and inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) following Phase 3 randomized trials. The EXPosurE Registry RiociguaT in patients with pulmonary hypertension (EXPERT) study was designed to monitor the long-term safety of riociguat in clinical practice. Methods: EXPERT was an international, multicenter, prospective, uncontrolled, non-interventional cohort study of patients treated with riociguat. Patients were followed for at least 1 year and up to 4 years from enrollment or until 30 days after stopping riociguat treatment. Primary safety outcomes were adverse events (AEs) and serious adverse events (SAEs) coded using Medical Dictionary for Regulatory Activities preferred terms and System Organ Classes version 21.0, collected during routine clinic visits and collated via case report forms. Results: In total, 956 patients with CTEPH were included in the analysis. The most common AEs in these patients were peripheral edema/edema (11.7%), dizziness (7.5%), right ventricular (RV)/cardiac failure (7.7%), and pneumonia (5.0%). The most common SAEs were RV/cardiac failure (7.4%), pneumonia (4.1%), dyspnea (3.6%), and syncope (2.5%). Exposure-adjusted rates of hemoptysis/pulmonary hemorrhage and hypotension were low and comparable to those in the long-term extension study of riociguat (Chronic Thromboembolic Pulmonary Hypertension Soluble Guanylate Cyclase-Stimulator Trial [CHEST-2]). Conclusion: Data from EXPERT show that in patients with CTEPH, the safety of riociguat in routine practice was consistent with the known safety profile of the drug, and no new safety concerns were identified

Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry

International audienc

Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry

International audienc

Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry

Objective: The soluble guanylate cyclase stimulator riociguat is approved for the treatment of adult patients with pulmonary arterial hypertension (PAH) and inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension following Phase 3 randomized trials. The EXPosurE Registry RiociguaT in patients with pulmonary hypertension (EXPERT) study was designed to monitor the long-term safety of riociguat in clinical practice. Methods: EXPERT was an international, multicenter, prospective, uncontrolled, non-interventional cohort study of patients treated with riociguat. Patients were followed for at least 1 year and up to 4 years from enrollment or until 30 days after stopping riociguat treatment. Primary safety outcomes were adverse events (AEs) and serious adverse events (SAEs) coded using Medical Dictionary for Regulatory Activities preferred terms and System Organ Classes version 21.0, collected during routine clinic visits (usually every 3-6 months) and collated via case report forms. Results: In total, 326 patients with PAH were included in the analysis. The most common AEs in these patients were dizziness (11.7%), right ventricular (RV)/cardiac failure (10.7%), edema/peripheral edema (10.7%), diarrhea (8.6%), dyspnea (8.0%), and cough (7.7%). The most common SAEs were RV/cardiac failure (10.1%), pneumonia (6.1%), dyspnea (4.0%), and syncope (3.4%). The exposure-adjusted rate of hemoptysis/pulmonary hemorrhage was 2.5 events per 100 patient-years. Conclusion: Final data from EXPERT show that in patients with PAH, the safety of riociguat in clinical practice was consistent with clinical trials, with no new safety concerns identified and a lower exposure-adjusted rate of hemoptysis/pulmonary hemorrhage than in the long-term extension of the Phase 3 trial in PAH